.png)
.png)
Latest news from BIA
The BioIndustry Association announces 2021 charity partnership with Ovarian Cancer Action
The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovarian cancer does today.
UK in spotlight at JP Morgan Healthcare conference 2021 with the largest acquisition of a privately listed UK biotech company on record
The largest acquisition of a private UK biotech company on record has been announced today, as the curtain raiser to the JP Morgan global Healthcare conference, with the news that Sanofi has acquired Kymab for $1.1bn with the possibility of further $350m milestone payments.
US investors flock to UK biotech as sector delivers strong outperformance in a turbulent 2020
Biotech companies on London stock markets delivered market-beating returns in 2020 and attracted new investors looking for growth in a turbulent year, according to new analysis published today by the UK BioIndustry Association (BIA) and Radnor Capital Partners.
BIA responds to publication of Rare Disease framework
Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA) said: “We are very encouraged by the publication of the Rare Disease Framework and in particular its focus on ensuring patient access to treatments. Science continues to advance and to deliver new treatments for rare diseases where no treatment has been available before.
CTI Clinical Trial & Consulting Recognized as a Top Enrolling Site in Janssen's ENSEMBLE Phase 3 COVID-19 Vaccine Trial
CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announces that their research site was one of the top enrolling sites for the Janssen Pharmaceutical Companies of Johnson & Johnson’s large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735. Johnson & Johnson announced the Phase 3 trial reached full enrollment in December.
Taiho and Astex Extend Strategic Oncology Collaboration with MSD Granting Exclusive License to SHP2 Program
Taiho Pharmaceutical Co, Ltd., (hereinafter Taiho) announces that it and Astex Pharmaceuticals (UK), (hereinafter Astex), both Otsuka group companies, have granted an exclusive license under their joint, small-molecule drug discovery program targeting SHP2 to Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside the United States and Canada (hereinafter MSD) through a subsidiary.
OXGENE introduces SLIM platform for discovery of antibodies against membrane proteins
• Novel self-labelling mammalian display method for identifying antibodies against membrane proteins in their native configuration • Paper published in Journal of Biological Chemistry demonstrates compatibility with downstream manufacturing technologies to help accelerate CAR-T or antibody therapeutics development
Abzena announces opening of new biologics GMP manufacturing site with up to 12 X 2000L bioreactors
Abzena, a Global Partner Research Organization for integrated bench to market solutions for biologics and bioconjugates, has announced the addition of a 6th Global site that will augment cGMP manufacturing capacity for mammalian biologics. This expansion is driven by an increase in customer demand for commercial scale 2000L single use bioreactors across a wide range of therapeutic areas.
Guest Blog | All data matters and all matters data – how Health Data Research hubs are unlocking the power of data
In September this year, the seven initial Health Data Research Hubs celebrated their joint first birthday and reflected on their achievements over the past year. Set up as part of a four-year, £37 million investment from the UK Government Industrial Strategy Challenge Fund, the data hubs were designed to create a UK-wide system for the safe and responsible use of health-related data on a large scale.
CEO Update | Monday 11 January
This week’s CEO blog covers the largest acquisition of a privately listed UK biotech company on record, new positive analysis of biotech stocks, our preparations for the J.P. Morgan Healthcare conference, the latest on COVID-19 vaccinations and a look ahead to our first virtual event of the year based on work of member companies in the North West of England.
CEO Update | Monday 04 January
Happy New Year! 2021 got off to a promising start with the rollout of more innovative COVID-19 vaccines, sector recognition in the New Year Honours and we are now getting to grips with what the UK-EU deal will mean for our sector.
Guest Blog | Covid-19: is the vaccine race over?
The last few months have signalled hope that we might soon see the end of the Covid-19 pandemic. Many vaccine candidates released positive results and now the gradual roll out of the vaccine has begun. What about the others who were also part of the race? What does this mean for their efforts and essentially, is the vaccine race over?
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector | BIA update: October 2019 - January 2020
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from October 2019 to January 2020.
Global and growing - UK biotech financing in 2019
New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019.
UK life sciences: Catalysing investment and growth
This updated interim report sets out how the UK life sciences sector is driving investment and growth and makes the case for increased cost-effective public investment in the sector.
BIA biotech manifesto 2019
The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector.
